EC approves Jazz Pharmaceuticals’ Ziihera for advanced biliary tract cancer - PMLiVE Approximately 26% of biliary tract cancer patients globally have HER2-positive disease

#gastrointestinalcancers #EC #JazzPharmaceuticals #Ziihera #zanidatamab #advancedbiliarytractcancer #biliarytractcancer #BTCpatients #HER2targetedbispecificantibody #HERIZONBTC01trial #gallbladdercancer #cholangiocarcinoma #advancedHER2positiveBTC #HER2targetedtherapy
pmlive.com/pharma_news/...